DOCSLIB.ORG

ADISINSIGHT Database Summary Sheet

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ADISINSIGHT Database Summary Sheet ADISINSIGHT (Adis R&D Insight) 0BSubject Weekly reports on new drugs in research, changes in development phases, and licensing Coverage availability 1BFile Type Substance, Full Text 2BFeatures Alerts (SDI) Weekly ® CAS Registry Page Images STN AnaVist™ Number® Identifiers ® Keep & Share SLART STN Easy Learning Database Structures • 3BRecord Full text reports, i.e., profiles, on drugs in active research and development by the Content international pharmaceutical industry • Generic names, synonyms, trade names ® • CAS Registry Numbers • EphMRA ATC codes, WHO ATC codes • Developing companies, development stages by indication and country • Licensed forecast information from Lehman Brothers • Adis's own unique therapeutic value rating 4BFile Size More than 45,730 records (8/19) 5BCoverage 1998 to the present 6BUpdates Weekly 7BLanguage English 8BDatabase Springer International Publishing AG Producer Copyright Holder Contact Springer Online Services support desk: Email: [email protected] Phone: +49 6221 345 4303 (Europe/Asia/Africa) +1 800 777 4643 (North & South America) • 9BSources Direct contact with companies involved with research and development • 1,700 biomedical and medical journals • International meetings and conferences • Company annual reports • News services • Press releases • Licensed Lehman Brothers' PharmaPipelines data August 2019 2 ADISINSIGHT 10BUser Aids • Online Helps (HELP DIRECTORY lists all help messages available) • STNGUIDE 11BClusters • ADISBASES • BIOSCIENCE • CASRNS • COMPANIES • FORMULATION • FULLTEXT • HEALTH • MEDICINE • PHARMACOLOGY • TOXICOLOGY STN Database Clusters information (PDF). 12BPricing Enter HELP COST at an arrow prompt (=>). August 2019 3 ADISINSIGHT Search and Display Field Codes The following fields that allow left truncation (/BI, /CNS and /RNTE) are marked with an asterisk. Search Display Search Field Name Code Search Examples Codes Basic Index* (contains single None S IMMUNOSTIMULANTS CC, CN, CO, words from the classification (or /BI) S ANTI-ATHER? DSTA, MF, RN, code (CC), development status S GLAXO (L) ORIGINATOR RNTE, TX (DSTA), text (TX), revision note S MECHANISM(L)IMMUNOMODULATORS (RNTE), company name (CO), S C (1W) GO chemical name (CN), controlled S VACCINE# (P) USE term (CT), and geographic term S C10H10N2O5 (GT) fields, as well as S 47931-85-1 molecular formulas (MF) and CAS Registry Numbers (RN)) Accession Number /AN S 1998:9493/AN AN Change Date (1) /CDAT S CDAT>19980100 CDAT S JULY 2, 1998/CDAT Chemical Name (includes /CN S POLOXAMER 188 NF/CN CN chemical names, generic names, synonyms, and trade names) Chemical Name Segment* /CNS S (METHYL (L) THIAZOL)/CNS CN S ?AMINOBUTYRYL?/CNS S (SALBUTAMOL AND SCHERING)/CNS Classification Code (EphMRA /CC S R03/CC CC ATC codes and WHO ATC S R3/CC codes) (code and text) (2) S "ANTI-ACNE PREPARATIONS"/CC S TOPICAL PREPARATIONS/CC Company Name (2) (corporate /CO S SMITHKLINE UNITED KINGDOM/CO CO name and location) S LICENSEE (L) INTROGEN/CO Controlled Term (indication) /CT S ALZHEIMER?/CT DSTA S ANXIETY DISORDERS/CT Development Status /DSTA S (PHASE II (L) GERMANY)/DSTA DSTA (development phase, location, S (STROKE (L) PRECLINICAL)/DSTA and indication) Document Number /DN S 002345/DN DN Element Count, Specific (1) /Element S 1/N AND 3/O MF symbol Entry Date (1) /ED S L1 AND ED>=19990700 Not displayed Field Availability /FA S EVALUATION/FA FA (code and text) S L1 AND RN/FA Geographic Term /GT S GERMANY/GT DSTA (code and text) S DE/GT Highest Development Phase /HDP S PHASE III/HDP HDP Journal Title /JT S ADIS R&D INSIGHT/JT JT, SO Molecular Formula /MF S C10H10N2O5/MF MF S C18 H22 N2 O S . Cl H/MF Number of Components (1) /NC S L6 AND NC>=2 MF Other Source (Adis Alerts /OS S "800007351"/OS OS Accession Number) Periodic Group /PG S T3/PG MF Reference /RE S JOURNAL OF PHARMACOLOGY/RE RE Revision Date (1) /RDAT S 19980312/RDAT RDAT August 2019 4 ADISINSIGHT Search and Display Field Codes (cont’d) Search Display Search Field Name Code Search Examples Codes Revision Note* /RNTE S PRECLINICAL DEV?/RNTE RNTE Source /SO S ADIS R&D INSIGHT/SO SO Trade Name /TN S TANADOPA/TN CN Update Date (1) /UP S L1 AND UP>=19990600 Not displayed Word Count (1) /WC S L1 AND WC WC (1) Numeric search field that may be searched using numeric operators or ranges. (2) Implied (S) proximity is available in this field. (3) This score is only available in selected records published in November 2010 and earlier. DISPLAY and PRINT Formats Any combination of formats may be used to display or print answers. Multiple codes must be separated by spaces or commas, e.g., D L1 1-5 CN TX. The fields are displayed or printed in the order requested. Hit-term highlighting is available for all fields except FA, STF, STR, and STS. Highlighting must be ON during SEARCH in order to use the HIT, KWIC, and OCC formats. Format Content Examples AN Accession Number D AN CC Classification Code (EphMRA ATC codes and WHO ATC codes) D 1-3 CC CDAT (1) Change Date D CDAT CN Chemical Name (Generic Names, Synonyms, Chemical Name, and Trade Names) D CN STR (includes TN) CO Company Name (corporate name and location) (Originator, Parent, Licensee, D CO 1,3-5 and Other) DN Document Number D AN DN DSTA Development Status (development status, location, and indication) D DSTA FA (2) Field Availability D FA HDP Highest Development Phase D HDP JT (2) Journal Title D JT 2 MF Molecular Formula D CN MF OS Other Source (Adis Alerts Accession Number) D OS RDAT (RNTE) Revision Date and Revision Note D RDAT RE Reference D RE L1 4 RN CAS Registry Number and Related CAS Registry Number D RN 3,4 SO Source D SO STF Flat Structure (no stereo indicated) D L9 1 3 STR (3) Structure Diagram (includes stereo bonds and R/S/E/Z labels when available) D L4 STR STS (2,3) Stereo Structure (includes stereo bonds when available) D STS TN (2) Trade Name D TN TX Text (Introduction, Evaluation, Commercial Summary (table with Company, Major D TX Markets, Launch Date, Commercial Value, and Patent Expiry), Pharmacology Overview (Mechanism of action, Route of Elimination), Clinical Overview, Adverse Events, Pharmacology (Pharmacokinetics, Clinical Studies), and Therapeutic Trials) (includes EVAL) WC Word Count D WC ALL (3) AN, SO, DN, CDAT, CN, MF, RN, STR, related RN, CC, HDP, DSTA, CO, OS, WC, D ALL TX, RDAT, RNTE, RE DALL (3) ALL, delimited for post-processing D DALL IALL (3) ALL, indented with text labels D IALL IDE (3) AN, SO, DN, CDAT, CN, MF, RN, STR, related RN, CC, HDP, CO, OS, WC D IDE IIDE (3) IDE, indented with text labels D L2 3 IIDE (IIDE is the default) D ISTD (3) STD, indented with text labels D ISTD August 2019 5 ADINSIGHT DISPLAY and PRINT Formats (cont’d) Format Content Examples SCAN (1,4) CN (Generic Name) (random display, no answer number) D SCAN STD (3) AN, SO, DN, CDAT, CN, MF, RN, STR, related RN, CC, HDP, DSTA, CO, OS, WC, D STD TX TRIAL (1) CN (Generic Name), CDAT D TRIAL (SAM, TRI) TOTAL HIT Fields containing hit terms D HIT KWIC Hit terms with 20 words on either side (KeyWord-In-Context) D KWIC NOH OCC (1) Number of occurrences of hit terms and fields in which they occur D OCC (1) No online display fee for this format. (2) Custom display format only. (3) Stereo structure diagrams are available only on graphics terminals and offline prints. (4) SCAN must be entered on the command line, i.e., DISPLAY SCAN, D SCAN. SELECT, ANALYZE, and SORT Fields The SELECT command is used to create E-numbers containing terms taken from the specified field in an answer set. The ANALYZE command is used to create an L-number containing terms taken from the specified field in an answer set. The SORT command is used to rearrange the search results in either alphabetic or numeric order of the specified field(s). ANALYZE/ Field Name Field Code SELECT (1) SORT Accession Number AN Y N CAS Registry Number RN Y (2) N CAS Registry Number and Chemical Name CHEM Y (3) N Change Date CDAT Y Y Chemical Name CN Y (4) N (default) NAME Y (5) N Classification Code (EphMRA and WHO ATC codes) CC Y Y Company Name (Corporation Name) CO Y Y Controlled Term (Indication) CT Y (6) N Development Status DSTA Y N Document Number DN Y Y Geographic Term GT Y (6) N Highest Development Phase HDP Y Y Journal Title JT Y Y Molecular Formula MF Y Y Occurrence Count of Hit Terms OCC N Y Other Source (Adis Alerts Accession Number) OS Y (7) Y Reference RE Y N Revision Date RDAT Y (6) N Revision Note RNTE Y (6) N Source SO Y N Text TX Y (8) N Trade Name TN Y N Word Count WC N Y (1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HIT CN. (2) Selects or analyzes the CAS Registry for the substance and the related CAS Registry Numbers with /BI appended to the terms created by SELECT. August 2019 6 ADISINSIGHT (3) Selects or analyzes the CAS Registry for the substance, the related CAS Registry Numbers, Generic Names, Synonyms, Chemical Name, and Trade Names) with /BI appended to the terms created by SELECT. (4) Selects or analyzes the Generic Names, Synonyms, Chemical Name, and Trade Names). (5) Selects or analyzes the Generic Names, Synonyms, Chemical Name, and Trade Names with /BI appended to the terms created by SELECT. (6) SELECT HIT and ANALYZE HIT are not valid with this field.
Load more

Recommended publications
  • Supplementary Appendix 1. Search Strategy for the Systematic Review and Meta-Analysis
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax Supplementary Appendix 1. Search strategy for the systematic review and meta-analysis # COVID-19 AND (ACEI or ARB) Pubmed #1. COVID-19 ((((novel[Title/Abstract]) AND (((corona[Title/Abstract]) AND virus[Title/Abstract]) OR (coronavirus[Title/Abstract]))) OR ((COVID[Title/Abstract]) OR (COVID-19[Title/Abstract]) OR (nCoV[Title/Abstract]) OR (2019-nCoV[Title/Abstract]) OR (Novel Coronavirus Pneumon.ia[Title/Abstract]) OR (NCP[Title/Abstract]) OR (severe acute respiratory infection[Title/Abstract]) OR (SARI[Title/Abstract]) OR (SARS-CoV-2[Title/Abstract]))) #2. ARB (("Angiotensin Receptor Antagonists"[Mesh]) OR (((angiotensin receptor blocker[Title/Abstract]) OR angiotensin receptor blockers[Title/Abstract]) OR ARB.*[Title/Abstract]) OR (((angiotensin[Title/Abstract]) AND receptor[Title/Abstract]) AND (antagonist.*[Title/Abstract] OR inhibitor.*[Title/Abstract] OR blocker.*[Title/Abstract]))) OR (ARB[Title/Abstract]) OR (olmesartan[Title/Abstract]) OR (valsartan[Title/Abstract]) OR (eprosartan[Title/Abstract]) OR (irbesartan[Title/Abstract]) OR (candesartan[Title/Abstract]) OR (losartan[Title/Abstract]) OR (telmisartan[Title/Abstract]) OR (azilsartan[Title/Abstract]) OR (tasosartan[Title/Abstract]) OR (embusartan[Title/Abstract]) OR (forasartan[Title/Abstract]) OR (milfasartan[Title/Abstract]) OR (saprisartan[Title/Abstract]) OR (zolasartan[Title/Abstract])
    [Show full text]
  • Cers Report Cover
    Future Research Needs Paper Number 8 Future Research Needs for Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease This report is based on research conducted by the Duke Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10066-I). The findings and conclusions in this document are those of the author(s), who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care researchers and funders of research make well-informed decisions in designing and funding research and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of scientific judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical research and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances. This report may be used, in whole or in part, as the basis for research design or funding opportunity announcements. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. This information does not represent and should not be construed to represent a determination or policy of the Agency for Healthcare Research and Quality or the U.S.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Supplementary Appendix 1. Search Strategy for the Systematic Review and Meta-Analysis
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax Supplementary Appendix 1. Search strategy for the systematic review and meta-analysis # COVID-19 AND (ACEI or ARB) Pubmed #1. COVID-19 ((((novel[Title/Abstract]) AND (((corona[Title/Abstract]) AND virus[Title/Abstract]) OR (coronavirus[Title/Abstract]))) OR ((COVID[Title/Abstract]) OR (COVID-19[Title/Abstract]) OR (nCoV[Title/Abstract]) OR (2019-nCoV[Title/Abstract]) OR (Novel Coronavirus Pneumon.ia[Title/Abstract]) OR (NCP[Title/Abstract]) OR (severe acute respiratory infection[Title/Abstract]) OR (SARI[Title/Abstract]) OR (SARS-CoV-2[Title/Abstract]))) #2. ARB (("Angiotensin Receptor Antagonists"[Mesh]) OR (((angiotensin receptor blocker[Title/Abstract]) OR angiotensin receptor blockers[Title/Abstract]) OR ARB.*[Title/Abstract]) OR (((angiotensin[Title/Abstract]) AND receptor[Title/Abstract]) AND (antagonist.*[Title/Abstract] OR inhibitor.*[Title/Abstract] OR blocker.*[Title/Abstract]))) OR (ARB[Title/Abstract]) OR (olmesartan[Title/Abstract]) OR (valsartan[Title/Abstract]) OR (eprosartan[Title/Abstract]) OR (irbesartan[Title/Abstract]) OR (candesartan[Title/Abstract]) OR (losartan[Title/Abstract]) OR (telmisartan[Title/Abstract]) OR (azilsartan[Title/Abstract]) OR (tasosartan[Title/Abstract]) OR (embusartan[Title/Abstract]) OR (forasartan[Title/Abstract]) OR (milfasartan[Title/Abstract]) OR (saprisartan[Title/Abstract]) OR (zolasartan[Title/Abstract])
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Self-Measured Compared to Office
    Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Supplemental Tables and Figures Part 1: Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension Table 1.1 Electronic search terms used for the current meta-analysis (Part 1 – Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension). PubMed Search (Blood Pressure Monitoring, Ambulatory [mesh] OR self care [mesh] OR telemedicine [mesh] OR patient participation [tiab] OR ambulatory [tiab] OR kiosk [tiab] OR kiosks [tiab] OR self-monitor* [tiab] OR self-measure* [tiab] OR self-care* [tiab] OR self-report* [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR home monitor* [tiab] OR telehealth [tiab] OR tele-health [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR telemedicine [tiab] OR patient-directed [tiab] OR Blood pressure monitoring “patient directed” [tiab] OR HMBP [tiab] OR SMBP [tiab] OR home [tiab] OR white coat [tiab] OR concept + Self Care concept ((patient participation [ot] OR ambulatory [ot] OR kiosk [ot] OR kiosks [ot] OR self-monitor* [ot] OR self-measure* [ot] OR self-care* [ot] OR self-report* [ot] OR telemonitor* [ot] OR tele-monitor* [ot] OR home monitor* [ot] OR telehealth [ot] OR tele-health [ot] OR telemonitor* [ot] OR tele- monitor* [ot] OR telemedicine [ot] OR patient-directed [tiab] OR “patient directed” [tiab]
    [Show full text]
  • Use of ACE Inhibitors for Lowering Serum Cholesterol
    Europaisches Patentamt European Patent Office Office europeen des brevets (TT) Publication number : 0 508 665 A2 12) EUROPEAN PATENT APPLICATION (2j) Application number : 92302822.9 © int. ci.5 : A61K 31/675, // (A61 K31/675, 31:22) (22) Date of filing : 31.03.92 (§) Priority: 01.04.91 US 677921 (72) Inventor : Aberg, A.K. Gunnar 519 Bergen Street Lawrenceville, New Jersey (US) (43) Date of publication of application : Inventor : Kowala, Mark 14.10.92 Bulletin 92/42 H-1 Shirley Lane Lawrenceville, New Jersey (US) Inventor : Ferrer, Patricia 33 Dublin Road @ Designated Contracting States : AT BE CH DE DK ES FR GB GR IT LI LU MC NL Pennington, New Jersey (US) PT SE (74) Representative : Thomas, Roger Tamlyn et al D. & Co. 10 Inn @ Applicant : E.R. SQUIBB & SONS, INC. Young Staple Lawrenceville-Princeton Road London WC1V 7RD (GB) Princeton New Jersey 08543-4000 (US) (54) Use of ACE inhibitors for lowering serum cholesterol. (57) A method is provided for lowering serum cholesterol and thereby inhibiting fatty streak lesions of atherosclerosis by administering to a patient a phosphorus-containing ACE inhibitor, such as fosinopril or ceronapril, alone or in combination with a cholesterol lowering drug, such as pravastatin. CM < If) CO CO 00 o If) LU Jouve, 18, rue Saint-Denis, 75001 PARIS EP 0 508 665 A2 The present invention relates to a method for lowering serum cholesterol in mammalian species by admin- istering a phosphorus-containing ACE inhibitor, such as fosinopril or ceronapril, alone or in combination with a cholesterol lowering drug, for example an HMG CoA reductase inhibitor, such as pravastatin, lovastatin or simvastatin.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Towards Better Fall Prevention
    TOWARDS BETTER FALL PREVENTION Examining the interplay between factors that influence gait in older patients Maartje de Groot TOWARDS BETTER FALL PREVENTION Examining the interplay between factors that influence gait in older patients PhD-thesis, Utrecht University, The Netherlands ISBN: 978-94-6295-634-6 Cover and layout: Maartje de Groot Printed by: ProefschriftMaken || Vianen © M.H. de Groot, Amsterdam, The Netherlands, 2017 All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any means, without written permission of the author or the publisher holding the copyright of the published articles. TOWARDS BETTER FALL PREVENTION Examining the interplay between factors that influence gait in older patients Op weg naar betere valpreventie – Een onderzoek naar de samenhang tussen factoren die het looppatroon van oudere patiënten beïnvloeden (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op woensdag 10 mei 2017 des middags te 4.15 uur door Maartje Helena de Groot geboren op 20 november 1986 te Aduard Promotor: Prof. dr. J.H. Beijnen Copromotor: Dr. C.J.C. Lamoth The research described in this thesis was carried out at the Department of Geriatric Medicine of the MC Slotervaart Hospital in Amsterdam in close collaboration with the Center for Human Movement Sciences of the University Medical
    [Show full text]
  • SUPPLEMENTARY MATERIAL 1: Search Strategy
    SUPPLEMENTARY MATERIAL 1: Search Strategy Medline search strategy 1. exp basal ganglia hemorrhage/ or intracranial hemorrhages/ or cerebral hemorrhage/ or intracranial hemorrhage, hypertensive/ or cerebrovascular disorders/ 2. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or pon$ or lentiform$ or brainstem or cortic$ or cortex$ or subcortic$ or subcortex$) adj5 (h?emorrhag$ or h?ematoma$ or bleed$)).tw 3. ((hemorrhag$ or haemorrhag$) adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw 4. (ICH or ICHs or PICH or PICHs).tw 5. 1 or 2 or 3 or 4 6. exp blood pressure/ 7. exp hypertension/ 8. (blood pressure or bloodpressure).tw 9. ((bp or blood pressure) adj5 (lowering or reduc$)).tw 10. ((strict$ or target$ or tight$ or intens$ or below) adj3 (blood pressure or systolic or diastolic or bp or level$)).tw 11. (hypertension or hypertensive).tw 12. ((manage$ or monitor$) adj3 (hypertension or blood pressure)).tw 13. ((intense or intensive or aggressive or accelerated or profound or radical or severe) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 14. ((standard or normal or ordinary or guideline or guide line or guideline recommend$ or recommend$ or convention$ or usual or established) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 15. (antihypertensive adj2 (agent$ or drug$ or medicat$)).tw 1 16. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 17.
    [Show full text]
  • Single Technology Appraisal Patiromer for Treating Hyperkalaemia
    Single Technology Appraisal Patiromer for treating hyperkalaemia [ID877] Committee Papers © National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SINGLE TECHNOLOGY APPRAISAL Patiromer for treating hyperkalaemia [ID877] Contents: The following documents are made available to consultees and commentators: 1. Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) 2. Comments on the Appraisal Consultation Document from the company 3. Consultee and commentator comments on the Appraisal Consultation Document from: a. Pumping Marvellous b. British Society for Heart Failure c. Renal Association d. Royal College of Pathologists 4. Comments on the Appraisal Consultation Document from experts: a. Professor John Cleland – clinical expert, nominated Vifor 5. Additional evidence submitted by the company a. Company evidence submission 1 b. Updated company evidence submission 2 (revised after ERG critique 2: section 1.4 added) c. Nephrologist survey d. Responses to questions from the ERG 6. Evidence Review Group critique of company comments on the ACD a. ERG critique of Evidence submission 2 (response to first Appraisal consultation) b. ERG addendum: Revised patiromer PAS and other company changes c. ERG response to US claims TTD data Any information supplied to NICE which has been marked as confidential, has been redacted. All personal information has also been redacted. © National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner.
    [Show full text]
  • Pharmacotherapy for Mild Hypertension (Review) – the Cochrane Collaboration
    Pharmacotherapy for mild hypertension (Review) Diao D, Wright JM, Cundiff DK, Gueyffier F This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2012, Issue 11 http://www.thecochranelibrary.com Pharmacotherapy for mild hypertension (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. T A B L E O F C O N T E N T S HEADER ....................................... 1 ABSTRACT ...................................... 1 PLAIN LANGUAGE SUMMARY .............................. 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . 2 BACKGROUND .................................... 5 OBJECTIVES ..................................... 5 METHODS ...................................... 5 RESULTS ....................................... 6 Figure 1. ..................................... 7 DISCUSSION ..................................... 8 Figure 2. ..................................... 9 AUTHORS’ CONCLUSIONS ............................... 10 ACKNOWLEDGEMENTS ................................ 10 REFERENCES ..................................... 10 CHARACTERISTICS OF STUDIES ............................. 13 DATA AND ANALYSES .................................. 19 Analysis 1.1. Comparison 1 Treatment versus No Treatment, Outcome 1 Mortality. 19 Analysis 1.2. Comparison 1 Treatment versus No Treatment, Outcome 2 Stroke. 20 Analysis 1.3. Comparison 1 Treatment versus No Treatment, Outcome 3 Coronary Heart Disease. 20 Analysis 1.4. Comparison 1 Treatment versus
    [Show full text]